UCB is a member of several industry associations around the world including the International Federation of Pharmaceutical Manufacturers & Associations , of which Jean-Christophe Tellier, UCB Chief Executive Officer & Chairman of the Executive Committee, is President. We are also members of the European Federation of Pharmaceutical Industries and Associations, the Pharmaceutical Research and Manufacturers of America in the U.S., the Biotechnology Innovation Organization in the U.S., the R&D-based Pharmaceutical Association Committee (RDPAC, China), and the Japan Pharmaceutical Manufacturers Association (JPMA, Japan).
UCB is also a member of various local chambers of commerce, healthcare stakeholder associations, and initiatives for sustainable development, and is represented on the board of several Belgian trade associations and organizations.
UCB also participates in several other international and regional associations that connect stakeholders to collaborate on key topics where we can bring our expertise and learn from others to provide solutions to key societal challenges. This includes such organizations as:
As part of our wider committed to UN SDG #3 to ensure healthy lives and promote wellbeing for all at all ages, we are engaged with Access Accelerated, a global initiative to tackle non-communicable diseases (NCDs).
UCB is investing in the ground-breaking AMR Action Fund , a cross-pharma industry initiative developed in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust to ensure there is a sustainable pipeline of new antibiotics.
UCB supports the Center for Global Health Innovation, an organization formed from the merger of the U.S. state of Georgia’s major global health and life science organizations, representing over 250 organizations and is focused on catalyzing collaboration, innovation, and coordination within the global health, health technology, and life sciences ecosystem.
UCB is the only biopharma company representative currently on the board of the Innovation and Value Initiative (IVI), an organization dedicated to advancing the science and improving the practice of value assessment in U.S. healthcare.
UCB is a member of the U.S. National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment that supports medical innovation.
UCB is part of PFMD on their mission to jointly define the future of healthcare with patients.
UCB is part of “the Shift”, working to co-create sustainable business models in Belgium.
UCB is one of 21 companies collaborating for the efficient, effective and high-quality delivery of new medicines.
We are collaborating to ensure product integrity and transparency across the supply chain with TAPA.